PMID- 21717071
OWN - NLM
STAT- MEDLINE
DCOM- 20111102
LR  - 20211020
IS  - 1559-0755 (Electronic)
IS  - 0257-277X (Print)
IS  - 0257-277X (Linking)
VI  - 50
IP  - 2-3
DP  - 2011 Aug
TI  - Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
PG  - 235-47
LID - 10.1007/s12026-011-8224-z [doi]
AB  - Dendritic cells (DCs) are the most powerful immunostimulatory cells specialized 
      in the induction and regulation of immune responses. Their properties and the 
      feasibility of their large-scale ex vivo generation led to the application of ex 
      vivo-educated DCs to bypass the dysfunction of endogenous DCs in cancer patients 
      and to induce therapeutic anti-cancer immunity. While multiple paradigms of 
      therapeutic application of DCs reflect their consideration as cancer "vaccines", 
      numerous features of DC-based vaccination resemble those of autologous 
      transplants, resulting in challenges and opportunities that distinguish them from 
      classical vaccines. In addition to the functional heterogeneity of DC subsets and 
      plasticity of the individual DC types, the unique features of DCs are the kinetic 
      character of their function, limited functional stability, and the possibility to 
      imprint in maturing DCs distinct functions relevant for the induction of 
      effective cancer immunity, such as the induction of different effector functions 
      or different homing properties of tumor-specific T cells (delivery of "signal 3" 
      and "signal 4"). These considerations highlight the importance of the application 
      of optimized, potentially patient-specific conditions of ex vivo culture of DCs 
      and their delivery, with the logistic and regulatory implications shared with 
      transplantation and other surgical procedures.
FAU - Kalinski, Pawel
AU  - Kalinski P
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213-1863, USA. 
      kalinskip@upmc.edu
FAU - Edington, Howard
AU  - Edington H
FAU - Zeh, Herbert J
AU  - Zeh HJ
FAU - Okada, Hideho
AU  - Okada H
FAU - Butterfield, Lisa H
AU  - Butterfield LH
FAU - Kirkwood, John M
AU  - Kirkwood JM
FAU - Bartlett, David L
AU  - Bartlett DL
LA  - eng
GR  - UL1 TR000005/TR/NCATS NIH HHS/United States
GR  - CA095128/CA/NCI NIH HHS/United States
GR  - CA138639/CA/NCI NIH HHS/United States
GR  - P30 CA047904/CA/NCI NIH HHS/United States
GR  - R01 CA095128/CA/NCI NIH HHS/United States
GR  - R01 CA138639/CA/NCI NIH HHS/United States
GR  - CA114931/CA/NCI NIH HHS/United States
GR  - CA137214/CA/NCI NIH HHS/United States
GR  - P50 CA121973/CA/NCI NIH HHS/United States
GR  - R21 CA114931/CA/NCI NIH HHS/United States
GR  - CA121973/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Immunol Res
JT  - Immunologic research
JID - 8611087
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Antigens, Neoplasm/immunology/metabolism
MH  - *Cancer Vaccines/therapeutic use
MH  - Dendritic Cells/*immunology/metabolism/*transplantation
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Lymph Nodes/immunology/metabolism
MH  - Neoplasms/*immunology/metabolism/prevention & control/*therapy
MH  - T-Lymphocytes/immunology/metabolism
PMC - PMC3695396
MID - NIHMS419264
EDAT- 2011/07/01 06:00
MHDA- 2011/11/04 06:00
PMCR- 2013/06/28
CRDT- 2011/07/01 06:00
PHST- 2011/07/01 06:00 [entrez]
PHST- 2011/07/01 06:00 [pubmed]
PHST- 2011/11/04 06:00 [medline]
PHST- 2013/06/28 00:00 [pmc-release]
AID - 10.1007/s12026-011-8224-z [doi]
PST - ppublish
SO  - Immunol Res. 2011 Aug;50(2-3):235-47. doi: 10.1007/s12026-011-8224-z.